MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BRESNICK, E.
Right arrow Articles by MOSSÉ, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BRESNICK, E.
Right arrow Articles by MOSSÉ, H.

Molecular Pharmacology, Vol 4, 173-180, Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics

Increased Activity of Enzymes for de Novo Pyrimidine Biosynthesis after Orotic Acid Administration

EDWARD BRESNICK 1, ERNEST D. MAYFIELD JR. 1, and HELENA MOSSÉ 1

1 Department of Pharmacology, Baylor University College of Medicine, Houston, Texas 77025

Administration of a purified diet supplemented with 1% orotic acid is attended by a marked elevation in the specific activities of liver aspartate transcarbamylase (ATC), ornithine transcarbamylase, and dihydroorotase (DHOase) and in alterations in the composition of the acid-soluble nucleotide pool. Return of the rats to the control diet is followed by an immediate reinstatement of the normal acid-soluble nucleotide composition and by a slower return of the enzyme activities to basal values. The half-life of the return has been calculated as 2.5 and 0.5 days, for ATC and DHOase, respectively. Both ATC and DHOase activities are augmented in regenerating liver derived from rats fed either control or orotic acid diet. The studies suggest that high intracellular concentrations of pyrimidine nucleotides may not "repress" the enzymes involved in the de novo synthesis of pyrimidines in mammalian liver.

Note:
ACKNOWLEDGMENTS This work was supported by a grant from the United States Public Health Service, CA06571, and by an institutional grant from the American Cancer Society, ACS IN 27 H No. 11.

Submitted on September 25, 1967







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics